Home › Funds › Stonepine Capital Management, LLC › ADMA
Stonepine Capital Management, LLC position in ADMA
ADMA BIOLOGICS INC · Health Care
Stonepine Capital Management, LLC reported holding 400,000 shares of ADMA (ADMA BIOLOGICS INC) in its Q3 2026 13F filing — a position valued at US$5.2M, representing 3.99% of its reported portfolio and ranking #6 among its reported holdings. Stonepine Capital Management, LLC has disclosed ADMA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's ADMA position evolved
Stonepine Capital Management, LLC first disclosed a stake in ADMA in Q3 2023 at 9,104,275 shares (US$32.6M). The position peaked in Q4 2023 at 9,222,617 shares, worth US$41.7M. Across 13 filings, Stonepine Capital Management, LLC increased the stake 1 time(s), trimmed it 7 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 400,000 shares valued at US$5.2M — a reduction of -340,000 shares quarter over quarter.. Notable position changes include a 63% trim in Q1 2024 (shares rose 69% over the following quarter), a 45% trim in Q2 2024 (shares rose 79% over the following quarter), a 46% trim in Q3 2026 (shares rose 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.10M | $32.59M | New |
| Q4 2023 | 9.22M | $41.69M | Add |
| Q1 2024 | 3.43M | $22.62M | Reduce |
| Q2 2024 | 1.87M | $20.91M | Reduce |
| Q3 2024 | 1.87M | $37.38M | Hold |
| Q4 2024 | 1.24M | $21.28M | Reduce |
| Q1 2025 | 810.00K | $24.30K | Reduce |
| Q2 2025 | 750.00K | $13.66M | Reduce |
| Q3 2025 | 739.00K | $10.83M | Reduce |
| Q4 2025 | 740.00K | $13.50M | Hold |
| Q1 2026 | 740.00K | $6.67M | Hold |
| Q2 2026 | 740.00K | $6.19M | Hold |
| Q3 2026 | 400.00K | $5.20M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ADMA and 13F data
ADMA (ADMA BIOLOGICS INC) is a Health Care company. 19 other funds we track also report a position in ADMA — the largest reported positions include Rubric Capital Management LP (US$78.2M), B Group, Inc. (US$27.3M), Nantahala Capital Management, LLC (US$26.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ADMA
- Rubric Capital Management LP 9.34M sh · $78.17M · Q2 2026
- B Group, Inc. 3.26M sh · $27.31M · Q2 2026
- Nantahala Capital Management, LLC 2.59M sh · $25.98M · Q3 2026
- Duquesne Family Office LLC 2.78M sh · $23.30M · Q2 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held ADMA?
Stonepine Capital Management, LLC has disclosed ADMA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Stonepine Capital Management, LLC's current position in ADMA?
As of Q3 2026, Stonepine Capital Management, LLC holds 400.00K shares of ADMA (ADMA BIOLOGICS INC), valued at $5.20M, representing 3.99% of its reported portfolio and ranking #6.
Has Stonepine Capital Management, LLC been buying or selling ADMA?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC reduced its position in ADMA. The position peaked in Q4 2023 at 9.22M shares.
Which other funds hold ADMA?
Other major institutional holders of ADMA include Rubric Capital Management LP, B Group, Inc., Nantahala Capital Management, LLC, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.